ImmuPharma (LON:IMM) Trading Up 28.6% - What's Next?

Key Points

• ImmuPharma plc (LON:IMM) experienced a significant increase in stock value, rising 28.6% to GBX 11.30 ($0.15), with trading volume nearly doubling the average.
• The company has a market capitalization of £56.47 million and posted a negative EPS of GBX (0.38) in its last earnings report.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, including its lead program Lupuzor™ for treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) rose 28.6% on Tuesday . The company traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). Approximately 17,007,168 shares traded hands during trading, an increase of 97% from the average daily volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Trading Up 28.6%

The company has a market capitalization of £56.47 million, a PE ratio of -1,269.66 and a beta of 1.53. The stock has a fifty day moving average of GBX 5.30 and a two-hundred day moving average of GBX 3.58.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.